GlassScriptPhysician profile
Zabila Saeed
NPI 1578084232
$15,843.33
in general payments reported to CMS, 2019-2025
42 companies · $7,934 in 2025
The $7,934 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.33 · 2021: $99.95 · 2022: $123 · 2023: $343 · 2024: $7,327 · 2025: $7,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,600 · Honoraria: $5,375 · Food and Beverage: $3,898 · Travel and Lodging: $651 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,600.00 |
| Honoraria | $5,375.00 |
| Food and Beverage | $3,898.35 |
| Travel and Lodging | $651.33 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $6,114.69 | 2024-2025 | Onivyde |
| Deciphera Pharmaceuticals INC. | $5,906.06 | 2023-2025 | Qinlock |
| Astrazeneca Pharmaceuticals LP | $401.27 | 2024-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $330.13 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Eisai INC. | $287.20 | 2023-2025 | |
| Janssen Biotech, INC. | $230.61 | 2023-2025 | Darzalex, Rybrevant, Tecvayli |
| Lilly USA, LLC | $218.57 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $194.64 | 2023-2025 | |
| Incyte Corporation | $174.65 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Jazz Pharmaceuticals INC. | $151.38 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.61 | 2024-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $131.51 | 2023-2025 | Fruzaqla, Iclusig |
| Genentech USA, INC. | $117.83 | 2024-2025 | Itovebi, Venclexta, Lunsumio |
| Daiichi Sankyo INC. | $103.27 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Telix Pharmaceuticals | $100.00 | 2025 | Illuccix |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.09 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.02 | 2024-2025 | Libtayo |
| Exelixis INC. | $83.06 | 2023-2025 | Cabometyx |
| Geron Corporation | $83.03 | 2025 | Rytelo |
| Caris Mpi, INC. | $76.79 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $75.58 | 2023-2025 | Bavencio |
| Sumitomo Pharma America, INC. | $73.70 | 2024-2025 | Orgovyx |
| Glaxosmithkline, LLC. | $73.65 | 2024-2025 | Zejula, Jemperli |
| Abbvie INC. | $71.88 | 2023-2025 | Venclexta |
| Karyopharm Therapeutics INC. | $67.68 | 2024-2025 | Xpovio |
| Pharmaessentia USA Corporation | $50.68 | 2024 | Besremi |
| Springworks Therapeutics, INC. | $47.48 | 2024 | Ogsiveo |
| Beone Medicines USA, INC. | $41.97 | 2025 | Brukinsa, Tevimbra |
| Agios Pharmaceuticals, INC. | $41.56 | 2024-2025 | Pyrukynd |
| Amneal Pharmaceuticals LLC | $39.27 | 2023-2025 | Avastin, Alymsys |
| Tersera Therapeutics LLC | $38.85 | 2024 | Zoladex |
| G1 Therapeutics, INC. | $23.45 | 2023 | Cosela |
| Menarini Silicon Biosystems, INC. | $20.98 | 2025 | |
| Mirati Therapeutics, INC. | $20.38 | 2024 | Krazati |
| Puma Biotechnology, INC. | $20.11 | 2024 | |
| Genzyme Corporation | $18.82 | 2023 | |
| Acrotech Biopharma INC. | $17.57 | 2024 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $17.22 | 2024 | |
| Genmab U.S., INC. | $16.98 | 2023 | Epkinly |
| Celgene Corporation | $16.33 | 2019 | |
| Kyowa Kirin, INC. | $16.08 | 2025 | |
| Gilead Sciences, INC. | $14.70 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zabila Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.